Physician profile
Jennifer Lynn North
NPI 1205103884
$2,291.85
in general payments reported to CMS, 2019-2025
22 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $1,062 · 2023: $319 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.54 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $501.97 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $292.64 | 2021-2025 | |
| Janssen Biotech, INC. | $270.43 | 2021-2023 | Stelara, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $247.16 | 2021-2025 | |
| Genzyme Corporation | $158.65 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $125.00 | 2023 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $103.14 | 2022 | |
| Leo Pharma INC. | $82.01 | 2021-2022 | |
| Cvrx, INC. | $79.03 | 2023 | Barostim Neo System |
| Vyne Pharmaceuticals INC. | $71.76 | 2021 | |
| Almirall LLC | $65.50 | 2021-2022 | |
| Botanix Sb INC | $50.34 | 2025 | Sofdra |
| Incyte Corporation | $43.52 | 2022 | |
| Ucb, INC. | $32.17 | 2022 | |
| Pfizer INC. | $31.11 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.70 | 2021 | |
| Lilly USA, LLC | $24.62 | 2021 | |
| Biofrontera INC. | $19.70 | 2025 | Ameluz |
| E.R. Squibb & Sons, L.L.C. | $17.07 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.69 | 2021 | |
| Genentech USA, INC. | $15.20 | 2021 | |
| Nabriva Therapeutics, Plc | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer North listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.